Cardiotoxicity is one of the leading causes of drug attrition. It has been one of the main reasons for drug withdrawals, accounting for 45% of all drugs taken off the market between 1994 and 2006. However, cardiac drug safety is a major concern and one of the sticking points throughout cardiac drug development. Therefore, establishing in vitro assay at the early phases of drug development is critical in preventing late-stage failure.
In vitro cell’s culture are a powerful models for the accurate analysis of human heart disorders and therefore suitable to perform cardiotoxicity assays. Many of these disorders are the result of subtle changes to cardiomyocyte excitability, contractility, or both.
Our platform reveals the intracellular action potential you have been missing in fields such as cardiotoxicity and stem cell-derived cardiomyocyte differentiation, all label-free and in real-time. The cardiac action potential (AP), in fact, is vital for understanding and studied cardiac biology and drug safety .
Our tool demonstrated high reliability across different commercially available cardiomyocytes co-culture, with accurately measuring changes in depolarization, repolarization, and, indeed, detecting arrhythmias phenomena.